Novavax (NVAX)
(Delayed Data from NSDQ)
$9.35 USD
-0.26 (-2.71%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $9.42 +0.07 (0.75%) 7:58 PM ET
2-Buy of 5 2
D Value A Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$9.35 USD
-0.26 (-2.71%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $9.42 +0.07 (0.75%) 7:58 PM ET
2-Buy of 5 2
D Value A Growth D Momentum B VGM
Zacks News
Endo (ENDP) Gains on Deal to Acquire BioSpecifics for $540M
by Zacks Equity Research
Endo (ENDP) gains from the acquisition of commercial-stage biopharmaceutical company, BioSpecifics Technologies Corp.
Novavax (NVAX) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Novavax (NVAX) closed at $111.42 in the latest trading session, marking a -0.3% move from the prior day.
Vaxart (VXRT) Begins Dosing in Oral Coronavirus Vaccine Study
by Zacks Equity Research
Vaxart (VXRT) doses the first subject in an early-stage study of its oral coronavirus vaccine candidate VXA-CoV2-1. Stock rises.
Novavax (NVAX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Novavax (NVAX) closed at $111.02, marking a +0.93% move from the previous day.
Small-Caps, Energy Win the Trading Day
by Mark Vickery
The Energy sector was one of the biggest winners on the day, coming after weeks of hard-hit commodity prices finally getting a little traction.
Biotech Stock Roundup: REGN's Cocktail Data, GILD's RA Drug Approval & Other Updates
by Zacks Equity Research
The biotech sector remains in focus with regulatory and other pipeline updates.
Novavax (NVAX) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Novavax (NVAX) closed at $108.35 in the latest trading session, marking a +0.37% move from the prior day.
CureVac Begins Phase IIa Study on Coronavirus Vaccine Candidate
by Zacks Equity Research
CureVac (CVAC) doses the first patient in a phase IIa study on its COVID-19 vaccine candidate CVnCoV. Shares rise in after-hours trading following this development.
Endo Up on COVID-19 Vaccine Manufacturing Deal with Novavax
by Zacks Equity Research
Endo (ENDP) and Novavax enter a manufacturing agreement for the latter's COVID-19 vaccine candidate, NVX-CoV2373.
Company News for Sep 28, 2020
by Zacks Equity Research
Companies In The News Are: TCOM, BA, NVAX, HON.
Keysight, Mesa, Costco and Novavax as Zacks Bull and Bear of the Day
by Zacks Equity Research
Keysight, Mesa, Costco and Novavax as Zacks Bull and Bear of the Day
Novavax Begins Phase III Study on Coronavirus Vaccine in the UK
by Zacks Equity Research
Novavax (NVAX) starts a phase III efficacy study on its COVID-19 vaccine candidate NVX-CoV2373 in the United Kingdom. Stock rises in after-hours trading.
Rollercoaster Market for Thursday
by Mark Vickery
The major indexes gained less than 1% in total Thursday: +0.37% on the Nasdaq, +0.30% on the S&P 500, +0.20% on the Dow and +0.02% for the Russell 2000.
The Zacks Analyst Blog Highlights: NVAX, MRNA, VIR and BNTX
by Zacks Equity Research
The Zacks Analyst Blog Highlights: NVAX, MRNA, VIR and BNTX
4 Biotechs That Have More Than Doubled Thanks to Coronavirus
by Kinjel Shah
Stocks of several small biotech companies more than double so far this year as they taste success in their efforts to make a vaccine/medicine for treating COVID-19.
Novavax (NVAX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Novavax (NVAX) closed the most recent trading day at $110.15, moving +1.65% from the previous trading session.
Novavax Expands Coronavirus Vaccine Manufacturing Deal in India
by Zacks Equity Research
Novavax (NVAX) amends its present contract with Serum Institute of India Private Limited to widen the manufacturing capacity of its COVID-19 vaccine candidate NVX-CoV2373 to 2 billion plus doses in 2021.
Vaxart Gets FDA Nod for Phase I Study on Coronavirus Vaccine
by Zacks Equity Research
Vaxart's (VXRT) investigational new drug application for oral coronavirus vaccine candidate gets a clearance from the FDA. The company will begin a phase I study later this month.
Why Is Novavax (NVAX) Down 42.9% Since Last Earnings Report?
by Zacks Equity Research
Novavax (NVAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Coronavirus Vaccine Efforts Hit as AstraZeneca Halts Study
by Kinjel Shah
Amid rising optimism on timely approval of a safe vaccine, the vaccine development efforts of AstraZeneca (AZN) have hit a roadblock.
Implied Volatility Surging for Novavax (NVAX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Novavax (NVAX) stock based on the movements in the options market lately.
Novavax to Supply Coronavirus Vaccine to Canadian Government
by Zacks Equity Research
Novavax (NVAX) signs a contract with the Government of Canada for supplying up to 76 million doses of its COVID-19 vaccine NVX-CoV2373, if approved.
Biotech Stock Roundup: BMY to Buy Forbius, BMRN Gets CRL & Other Updates
by Zacks Equity Research
The biotech sector remains in focus with drug approvals, and regulatory and other pipeline updates.
5 Sectors Set to Boom on Coronavirus Vaccine Optimism: Top Picks
by Sweta Killa
While the prospect of a COVID-19 treatment will lead to broad-based gains, some investing areas are expected to benefit the most.
The Zacks Analyst Blog Highlights: Emergent Biosolutions, Horizon, Novavax, Celldex and Aileron Therapeutics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Emergent Biosolutions, Horizon, Novavax, Celldex and Aileron Therapeutics